
Wegovy Tablet
Prescription Oral GLP-1 Weight Management Treatment Wegovy Tablet is a once-daily prescription medication designed to support long-term weight management in eligible adults when combined with a reduced-calorie diet and increased physical activity.
Convenient Once-Daily Tablet An oral GLP-1 treatment that helps regulate appetite, reduce food intake, and support weight loss without injections.
Multiple Dosage Strengths Available in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths to support individualized treatment plans as prescribed by a healthcare provider.
Prescription-Only Treatment Requires a medical evaluation and valid prescription from a licensed healthcare provider to determine eligibility and appropriate dosing.
Manufactured by Novo Nordisk An FDA-approved prescription GLP-1 medication developed by Novo Nordisk for chronic weight management in eligible patients.
Prescription Oral GLP-1 Weight Management Treatment
Wegovy Tablet is a once-daily prescription GLP-1 medication containing semaglutide, designed to support long-term weight management in eligible adults. When combined with a reduced-calorie diet and increased physical activity, Wegovy helps regulate appetite, reduce food intake, and support weight loss. This information is for educational purposes and does not replace professional medical advice.
Product Specifications
Product Name: Wegovy Tablet
Category: Prescription Weight Management
Active Ingredient: Semaglutide
Available Strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg
Form: Oral Tablet
Manufacturer: Novo Nordisk
Availability: Prescription only
Important Dosing Instructions
Wegovy Tablets are taken orally once daily in the morning on an empty stomach with up to 4 ounces of plain water. Swallow the tablet whole without crushing, chewing, or splitting it. Wait at least 30 minutes before eating, drinking beverages other than water, or taking other oral medications. Follow your healthcare providers prescribed dosing schedule.
Key Features
Convenient Oral GLP-1 Treatment: A once-daily tablet that provides a prescription weight management option without injections.
Multiple Dosage Strengths: Available in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths to accommodate prescribed dose escalation and ongoing treatment.
Appetite Regulation: Semaglutide acts on GLP-1 receptors involved in appetite regulation, helping reduce hunger and food intake.
Prescription-Only Medication: Requires an evaluation and valid prescription from a licensed healthcare provider.
Manufactured by Novo Nordisk: Developed by Novo Nordisk, a pharmaceutical manufacturer specializing in diabetes and weight management treatments.
Who May Benefit
Adults living with obesity who are seeking medically supervised weight management.
Adults who are overweight and have at least one weight-related medical condition.
Patients seeking a once-daily oral alternative to injectable weight management medications.
Individuals who qualify for GLP-1 treatment following an evaluation by a licensed healthcare provider.
Important Safety Information
Wegovy Tablet is a prescription medication that requires medical evaluation. Your healthcare provider will review your medical history, current medications, and overall health to determine whether treatment is appropriate.
Boxed Warning and Contraindications: Wegovy carries a boxed warning regarding thyroid C-cell tumors observed in rodents. It is unknown whether Wegovy causes these tumors, including medullary thyroid carcinoma (MTC), in humans. Do not use Wegovy if you have a personal or family history of MTC, have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or have experienced a serious allergic reaction to semaglutide or any of its ingredients.
Common Side Effects: Side effects may include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and other gastrointestinal symptoms. Discuss persistent or severe side effects with your healthcare provider.
Warnings and Precautions: Serious risks may include pancreatitis, gallbladder problems, dehydration-related kidney injury, and severe gastrointestinal reactions. Tell your healthcare provider about all medical conditions, medications, and any planned procedures requiring anesthesia or deep sedation. Wegovy should not be combined with other semaglutide-containing products or other GLP-1 receptor agonists.
Pregnancy: Wegovy should not be used for weight management during pregnancy. Patients planning pregnancy should discuss discontinuing semaglutide at least two months before attempting to conceive.
Directions for Use
Take Wegovy Tablet exactly as prescribed by your licensed healthcare provider. Treatment generally involves gradual dose increases to help improve gastrointestinal tolerability. Do not change your dose, discontinue treatment, or combine Wegovy with other weight management medications without consulting your healthcare provider.
Storage and Disposal
Store Wegovy Tablets according to the manufacturers instructions and the prescription label. Keep the medication in its original packaging, protected from moisture, and out of reach of children and pets. Do not use expired medication. Ask your pharmacist about proper disposal of unused or expired tablets. Never share prescription medication with another person.
